Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Some cases expand on earlier initiatives, like the Valsartan cases. The theory against these was launched from the Zantac ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead. Just over a week ago, Judge Vivian ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

Proton pump inhibitors (PPIs) are widely used medications to manage common digestive issues like heartburn, acid reflux, and ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a ...

The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.